Univ.-Prof. Dr. med. Tim H. Brümmendorf

Porträtfoto eines Mannes mit kurzen, hellen Haaren und einer hohen Stirn. Er trägt eine blaue Krawatte und einen weißen Arztkittel und lächelt freundlich in die Kamera.

Klinikdirektor

Univ.-Prof. Dr. med. Tim H. Brümmendorf
Tel.: 0241 80-89805
Fax: 0241 80-82449
madrianukaachende

 

Spezialgebiete: 

  1. Diagnostik und Therapie von Erkrankungen des blutbildenden Systems (Hämatologie)
  2. Systemtherapie onkologischer Erkrankungen
  3. Integrative Onkologie und Partizipative Entscheidungsfindung (SDM)

 

Wissenschaftliche Schwerpunkte:

  1. Akute und chronische Leukämien sowie Myeloproliferative Neoplasien
  2. Erbliche and erworbene Knochenmarkversagenserkrankungen (Aplastische Syndrome) und Tumorprädispositionssyndrome (z.B. Telomeropathien) des Erwachsenen
  3. Personalisierte Therapie bösartiger Erkrankungen (Molekular zielgerichtete Therapie sowie Zell- und Immuntherapie)

 

Publikationen (Auswahl):

  1. Kaiser A, Lysenko V, Myburgh R, Volta L, Pellegrino C, Theocharides APA, Christen D, Panse J, Bühler MM, Arock M, Butterfield J, de Toledo MAS, Valent P, Zenke M, Brümmendorf TH, Manz MG. CAR T-cells targeting CD117 effectively eliminate mast cells in preclinical models of advanced systemic mastocytosis. Leukemia 2026 May 7. doi: 10.1038/s41375-026-02968-5.
  2. Kim DDH, Zackova D, Breccia M, Lang F, Sakaida E, Jiang Q, De Paz R, Liu B, Isfort S, Yeung D, Takaku T, Brümmendorf TH. Underreported and underreviewed: Addressing the gaps in TKI tolerability literature for chronic myeloid leukemia.Blood Rev. 2026 Apr;76:101366. doi: 10.1016/j.blre.2026.101366
  3. Tometten M, Beier F, Kirschner M, Schumacher Y, Walter J, Vieri M, Kricheldorf K, Röth A, Platzbecker U, Radsak M, Schafhausen P, Corbacioglu S, Höchsmann B, Balabanov S, Hinze C, Chromik J, Heuser M, Kreuter M, Wlodarski MW, Elbracht M, Kurth I, Koschmieder S, Panse J, Isfort S, Meyer R, Brümmendorf TH. Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort. Blood Adv. 2025 May 13;9(9):2183-2191. doi: 10.1182/bloodadvances.2024014632
  4. Rolles B, Tometten M, Meyer R, Kirschner M, Beier F, Brümmendorf TH. Inherited Telomere Biology Disorders: Pathophysiology, Clinical Presentation, Diagnostics, and Treatment.Transfus Med Hemother. 2024 Jul 30;51(5):292-309. doi: 10.1159/000540109
  5. Petermann-Meyer A, Panse JP, Bremen R, Dohmen M, Drueke B, Geiser F, Haastert B, Heier L, Heuser C, Holsteg S, Icks A, Karger A, Nakata H, Viehmann A, Brümmendorf TH, Ernstmann N. Effectiveness of a comprehensive support program for families with parental cancer (Family-SCOUT): results of a multicenter non-randomized controlled trial. ESMO Open. 2024 Jun;9(6):103493. doi: 10.1016/j.esmoop.2024.103493.
  6. Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Ann Hematol. 2022 Dec 23. doi: 10.1007/s00277-022-05080-7. Online ahead of print. PMID: 36564535
  7. Brümmendorf TH*, Cortes JE*, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, Garcia-Gutierrez V, Chuah C, Kota V, Lipton JH, Rousselot P, Mauro MJ, Hochhaus A, Hurtado Monroy R, Leip E, Purcell S, Yver A, Viqueira A, Deininger MW; BFORE study investigators. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022; 36(7):1825-33. doi: 10.1038/s41375-022-01589-y. *equal contribution
  8. Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, Stalmann USA, Büsche G, Kreipe H, Gütgemann I, Krebs P, Banz Y, Boor P, Tai EW, Brümmendorf TH, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG, Schneider RK. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021; 28(4):637-652
  9. Cortes JE, Gambacorti-Passerini C, Deininger M, Mauro M, Chuah C., Kim D-W, Dyagil I,  Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial J. Clin Oncol 2018; 36(3):231-237
  10. Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, Beier F, Brümmendorf TH, Germing U, Platzbecker U, Büsche G, Knüchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley RC, Carr SA, Ebert BL. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016; 22(3):288-97
  11. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brümmendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012, 119(15):3403-3412.
  12. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008; 111(8):4355-4364.
  13. Balabanov S, Gontarewicz A, Ziegler P, Hartmann U, Kammer W, Copland M, Brassat U, Priemer M, Hauber I, Wilhelm T, Schwarz G, Kanz L, Bokemeyer C, Hauber J, Holyoake TL, Nordheim A, Brümmendorf TH. Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2007, 109(4):1701-1711.
  14. Brümmendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM.Blood. 2001 Feb 15;97(4):895-900. doi: 10.1182/blood.v97.4.895.
  15. Brümmendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 2000, 95(6):1883-1890.
  16. Rufer N*, Brümmendorf TH*, Kolvraa S, Bischoff C, Christensen K, Wadsworth L, Schulzer M, Lansdorp PM. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999; 190(2):157-167. *equal contribution